Short Title
|
Study
|
Investigator
|
| |
|
|
| |
Developmental Therapeutics: |
|
| ADVL0413 |
A Phase I Study of Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (Bay 43-9006) in Children with Refractory Solid Tumors or Refractory Leukemias |
Stewart Goldman, MD |
| ADVL0813 |
A Phase Istudy of IMC-A12 in Combination with CCI-779 (Temsirolimus) n Pediatric Patients with Recurrent or Refractory Solid Tumors |
Stewart Goldman, MD |
| ADVL0816 |
A Phase I Study of Obatoclax (Pan Anti-Apoptotic BCL-2 Family Small Molecule Inhibitor), in Combination with Vincristine/Doxorubicin/Dexrazoxane, in Children with Relapsed/Refractory Solid Tumors or Leukemia |
Stewart Goldman, MD |
| ADVL0911 |
A Phase I Dose Escalation Study of Seneca Valley Virus (NTX-010), A Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, Ewing Family of Tumors or Rare Tumors with Neuroendocrine Features |
Stewart Goldman, MD |
| ADVL0912 |
A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-MET, in Children with Relapsed / Refractory Solid Tumors and Anaplastic Large Cell Lymphoma |
Stewart Goldman, MD |
| ADVL0918 |
.A Phase 1 Study of Temsirolimus in combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors |
Stewart Goldman, MD |
| ADVL1011 |
A Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refactory Solid Tumors, leukemias and Myeloproliferative Neoplasms |
Stewart Goldman, MD
|
| ADVL1013 |
A Phase 1 study of MK-2206, an AKT Inhibitor, In Pediatric Patients with Recurrent or Refactory Solid Tumors or Leukemia
|
Stewart Goldman, MD |
| ADVL1014 |
A Phase 1 Dose Escalation Study of REOLYSIN, a Replication Competent Reovirus, in Pediatric Patients with Relapsed or Refractory Solid Tumors
|
Stewart Goldman, MD |
| ADVL1112 |
A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma |
Stewart Goldman, MD |
| |
|
|
Short Title
|
Newly Diagnosed CNS Tumors
|
Investigator
|
| |
|
|
| |
Ependymoma |
|
| ACNS0831 |
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1 to 21 |
Stewart Goldman, MD |
| CARBOSURVIVIN |
A Phase II Multi-Institutional Trial of Focal Radiotherapy with Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children with Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively |
Jason Fangusaro, MD |
| |
|
|
| |
High-Grade Glioma and Brain Stem Glioma |
|
| HGG TX |
A Pilot Study of Bevacizumab-Based Therapy in Patients with Newly Diagnosed High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas
|
Stewart Goldman, MD |
| ACNS0621 |
Cilengitide in Recurrent or Progressive and Refractory Childhood High-Grade Glioma |
Stewart Goldman, MD |
| ACNS0822 |
A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab (IND # 7921) and Temozolomide in Newly Diagnosed High Grade Glioma |
Steart Goldman, MD |
| ACNS0927 |
A Phase 1/2 Study of Suberoylanilide Hydroxamic Acid (SAHA, Vorinostat) and Local Irradiation, Followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) |
Stewart Goldman, MD |
| PBTC-033 |
A Phase I/II Study of ABT-888, an Oral Poly (ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with newly Diagnosed Pontine Gliomas (DIPG) |
Stewart Goldman, MD |
| |
|
|
| |
Medulloblastoma |
|
| ACNS0331 |
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy 18.00 Gy and Chemotherapy In Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial |
Stewart Goldman, MD |
| ACNS0332 |
Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients |
Stewart Goldman, MD |
| ACNS0333 |
Treatment of Atypical Teratoid/Rhabdoid Tumors of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation |
Stewart Goldman, MD |
| ACNS0334 |
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 months Old with Intensive Induction Chemotherapy with Methotrexate Followed by Consolidation with Stem Cell Rescue vs. the Same Therapy Without Methotrexate |
Stewart Goldman, MD |
| PBTC-026 |
A Feasibility Study of SAHA combined with Isotretinoin and Chemotherapy in infants with Embryonal Tumors of the Central Nervous System |
Stewart Goldman, MD |
| PBTC-032 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma |
Stewart Goldman, MD |
| |
|
|
| |
Germ Cell Tumors |
|
| |
|
|
| |
Neurofibromatosis and Malignant Peripheral Nerve Sheath Tumors (MPNST) |
|
| CNS 1007 |
Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Unresectable Malignant Peripheral nerve Sheath Tumors |
Stewart Goldman, MD |
| CNS 0808 |
A Phase II Trial of Peginterferon alfa-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas |
|
CNS 0808
|
A Phase II Trial of Peginterferon alfa-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas
|
Stewart Goldman, MD |
| |
|
|
| |
Relapsed, Refractory or Progressive Brain Tumors |
|
| ACNS0821 |
Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab (NSC# 704865,BB-IND# 7921) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COGRandomized Phase II Screening Trial |
Stewart Goldman, MD |
| PBTC-020 |
A Phase I Clinical Trial of AZD2171 in Children with Recurrent or Progressive Central Nervous System (CNS) Tumors |
Stewart Goldman, MD |
| PBTC-027 |
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors |
Steart Goldman, MD |
| PBTC-031 |
A Phase I and Pharmacokinetic Trial of PTC299 in Pediatric Patients with Refractory or Recurrent CNS Tumors
|
Stewart Goldman, MD |
| |
|
|
| |
Relapsed, Refractory or Progressive High-Grade Gliomas (including Brainstem Glioma) |
|
| |
|
|
| |
Relapsed, Refractory or Progressive Low-Grade Glioma |
|
| |
|
|
| |
Relapsed, Refractory or Progressive Ependymoma |
|
| CERN 08-01 |
A Phase II Study of Bevacizumab and Lapatinib in Children with Recurrent or Refractory Ependymoma |
Stewart Goldman, MD |
| OSI-774-205 |
A Randomized, Phase 2 Study of Single-agent Erlotinib versus oral Etoposide in Patients with recurrent or Refractory Pediatric Ependymoma |
Stewart Goldman, MD |
| OSI-774-206 |
Open-Label, Phase 2 Study of Single-agent Erlotinib for Patients with pediatric Ependymoma previously Treated with Oral Etoposide in Protocol OSI-774-205 |
Stewart Goldman, MD |
| |
|
|
| |
Relapsed, Refractory or Progressive Medulloblastoma |
|
| PBTC-025B |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Adults with Recurrent or Refractory Medulloblastoma |
Stewart Goldman, MD |
| PBTC-027 |
A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-ribose) Polymerase and Temozolomide in Children with Recurrent/Refractory CNS Tumors |
Stewart Goldman, MD |
| PBTC-032 |
A Phase II Clinical Trial Evaluating the Efficacy and Safety of GDC-0449 in Children with Recurrent or Refractory Medulloblastoma |
Stewart Goldman, MD |
| |
|
|
| |
Neoplastic Meningitis |
|
| |
|
|
| |
Brain Tumor Biology Studies |
|
| CERN 08-02 |
Ependymoma Tissue Correlates to Prognosis and Response to Therapy |
Stewart Goldman, MD |
| HGG LAB |
Biological characteristics of pediatric high grade gliomas |
Stewart Goldman, MD |
| Medullo/PNET |
Prognostic Capability of Telomerase Activity in Incident Cases of Pediatric Medulloblastomas and Primitive Neuroectodermal Tumors |
Stewart Goldman, MD |
| CMH11H01 |
A Feasibility Study of Circulating MicroRNAs as Disease Markers in Pediatric Cancers |
Rishi Lulla, MD |
| PBTC-N11 |
Immunologic Profile of Patients with Newly Diagnosed Medulloblastoma at Initial Diagnosis and During Standard Radiation and Chemotherapy |
Stewart Goldman, MD |
| Blood/CSF |
Collection of Blood and Cerebrospinal fluid for Pediatric Brain Tumor Research |
Rishi Lulla, MD |
| Rest |
Study of RE1 Silencing Transcription (REST) Factor and the REST pathjway as a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma and other Pediatric Neural Tumors. |
Jason Fangusaro, MD |
| |
|
|
| |
Miscellaneous |
|
| CMH 10CC08 |
A Phase II study of Acupuncture for the Treatment of Cancer Related Fatigue in Children and Adolescents with Central nervous System Tumors |
Rishi Lulla, MD |
| CMH11Q01 |
A Prospective study evaluating the role of dietary intake and nutritional status on neuropathy, functional measures of quality of life, and fatifue in chicldren receiving treatment for a brain tumor |
Stewart Goldman, MD |
| XERECEPT |
A Phase I/II Open Label Individual Dose Titration Trial of the Human Corticotropin- Releasing Factor (hCRF), Corticorelin Acetate Injection (Xerecept), to determine the tolerability of Xerecept in a Pediatric Population |
Stewart Goldman, MD |
| CMH11Q04 |
Long-Term Impact of Posterior Fossa Mutism on Quality of Life |
Jeffrey Rubens, MD |
| Thalamic Tumors-CMH |
Thalamic Tumors: the CMH experience |
Jason Fangusaro, MD |